ClinicalTrials.Veeva

Menu

A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province

Z

Zhongnan Hospital

Status

Active, not recruiting

Conditions

COVID-19
Ocular Surface Disease

Treatments

Other: NOT

Study type

Observational

Funder types

Other

Identifiers

NCT06355128
20240307

Details and patient eligibility

About

To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022

Full description

During late 2022 COVID-19 pandemic ocular discomforts were common in people with mild systemic symptoms, but most resolve on their own without any treatment. The disease spectrum of ophthalmology outpatient clinics is affected by the COVID-19 pandemic. In our study, we observed that the incidence of keratitis and acute angle-closure glaucoma in Phase A was significantly higher than that in Phase B and C.

Enrollment

16,000 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. 2022.12.7 to 2023.2.6 People surveyed by wechat Questionnaire Star 2. 2021.12.7 to 2022.1.6 and 2022.11.7 to 2023.1.6 Patients who received ophthalmology treatment in Zhongnan Hospital of Wuhan University and Qichun People's Hospital

Exclusion criteria

    1. currently hospitalized patients. 2. severe patients. 3. Incomplete information. 4. cannot be contacted by telephone. 5. Refuse questionnaire survey. 6.The electronic medical record information is incomplete. 7. Those who do not go to the ophthalmic clinic after registration. 8.severe patients. 9. Cannot be contacted by phone.

Trial design

16,000 participants in 3 patient groups

the pandemic period (Phase A)
Description:
the pandemic period (Phase A)
Treatment:
Other: NOT
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).
Description:
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
Treatment:
Other: NOT
the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).
Description:
the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).
Treatment:
Other: NOT

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems